None listed
Conditions
Brief summary
RECORD-AF study will enroll participants with a clinical diagnosis of atrial fibrillation (AF). This study will assess development of stroke and cognitive decline overtime, as well as record mortality rate among patients with AF. The primary objectives of this study are: 1. Assess the interaction of baseline AF health literacy, social determinants of health and biological aging the incidence of long-term outcomes such as: a) heart failure (HF) (HF preserved ejection fraction (EF), HF midrange EF, and HF reduced EF); b) mortality; c) stroke; d) cognitive decline and e) progression of AF Secondary objectives of this study are: 1. Determine the impact of blood pressure variability on long-term outcomes, in particular cognitive impairment, in patients with paroxysmal and non-paroxysmal AF. 2. Determine factors associated with development of tachycardia induced cardiomyopathy in AF patients.
Interventions
The study population will consist of participants with paroxysmal and non-paroxsmal atrial fibrillation (AF) or atrial flutter (AFI) with a diagnosis of non-valvular clinical atrial fibrillation (NVAF). Definition of clinical NVAF is based on 2018 Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation, which by accepted convention, a documented episode lasting at least 30 seconds is diagnostic.
Clinical investigation data for patients with AF will be collected at
The study population will consist of participants with paroxysmal and non-paroxsmal atrial fibrillation (AF) or atrial flutter (AFI) with a diagnosis of non-valvular clinical atrial fibrillation (NVAF). Definition of clinical NVAF is based on 2018 Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation, which by accepted convention, a documented episode lasting at least 30 seconds is diagnostic. Clinical investigation data for patients with AF will be collected at baseline and every 12 month, for a minimum of 5 years. Participants will attend an 1-hour consultation at the study hospital every 12 months. Other clinical data will be collected from their medical record in an ongoing basis.
Sponsors
The University of Adelaide
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
• Clinical diagnosis of AF • Capacity to provide informed consent
Exclusion criteria
• Less than12 months of life expectancy • Severe valvular disease i.e. mitral or aortic valve disease • Cardiac surgery in the last three months, or expected during first six months of study period • A recent history (< 1 year) of current malignancy, advanced heart failure (NYHA class IV), or end stage COAD or Interstitial lung disease other severe life-threatening comorbidities • Parkinson’s disease • Alzheimers disease • Aphasia • Severe psychiatric disorders e.g. schizophrenia, schizoaffective disorder or bipolar disorder • An inability to provide informed consent
Outcome results
None listed